AOD9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-11. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
=== Proposed names === In September 1992, the German group suggested the name nielsbohrium with symbol Ns to honor the Danish physicist Niels Bohr. The Soviet scientists at the Joint Institute for Nuclear Research in Dubna, Russia had suggested this name be given to element 105 (which was finally called dubnium) and the German team wished to recognise both Bohr and the fact that the Dubna team had been the first to propose the cold fusion reaction, and simultaneously help to solve the controversial problem of the naming of element 105. The Dubna team agreed with the German group's naming proposal for element 107. There was an element naming controversy as to what the elements from 104 to 106 were to be called; the IUPAC adopted unnilseptium (symbol Uns) as a temporary, systematic element name for this element. In 1994 a committee of IUPAC recommended that element 107 be named bohrium, not nielsbohrium, since there was no precedent for using a scientist's complete name in the naming of an element. This was opposed by the discoverers as there was some concern that the name might be confused with boron and in particular the distinguishing of the names of their respective oxyanions, bohrate and borate. The matter was handed to the Danish branch of IUPAC which, despite this, voted in favour of the name bohrium, and thus the name bohrium for element 107 was recognized internationally in 1997; the names of the respective oxyanions of boron and bohrium remain unchanged despite their homophony.
==== New Zealand ==== In 2017, the New Zealand government made changes to the regulations so that restrictions would be removed, which meant a doctor was able to prescribe cannabidiol to patients. The passing of the Misuse of Drugs (Medicinal Cannabis) Amendment Act in December 2018 means cannabidiol is no longer a controlled drug in New Zealand, but is a prescription medicine under the Medicines Act, with the restriction that "the tetrahydrocannabinols (THCs) and specified substances within the product must not exceed 2 percent of the total CBD, tetrahydrocannabinol (THC) and other specified substances."
(2026) reconstruct the demographic history of late Neanderthals on the basis of data from mitochondrial DNA, reporting evidence indicating that nearly all late Neanderthals from Europe belonged to a single mitochondrial DNA lineage, likely as a result of expansion across Europe from a refugium in southwestern France, and evidence of rapid decline in the effective population size of late Neanderthals shortly before their extinction; Sánchez Goñi & d'Errico (2026) link the presence of the refugium in southwestern France to the climatic configuration affecting western Europe 76,000 to 68,000 years ago. Bossoms Mesa et al. (2026) reconstruct the genetic diversity of late Neanderthals from Belgium and France, finding no evidence of mating among close relatives or genetic deterioration prior to Neanderthal extinction. Yousefi et al. (2026) study changes in suitability and connectivity of Neanderthal habitat through time, and find no evidence of habitat fragmentation caused by climate changes before Neanderthal extinction. Baykara et al. (2026) report evidence of sequential occupation of the Üçağızlı II Cave (Turkey) by Neanderthals and modern humans, and evidence of cultural continuity between members of the two human lineages occupying the site. Schoenemann et al. (2026) interpret differences in brain anatomy of Neanderthals and modern humans as falling within the range of differences between modern human populations, and find no evidence of significang cognitive differences between Neanderthals and modern humans that might have contributed to Neanderthal extinction.
Sources: en.wikipedia.org
Morgan William Sulzer (1884), governor of New York J. Mayhew Wainwright (1884), U.S. congressman and assistant secretary of war Charles Henry Turner (1888), U.S. congressman from New York; doorkeeper of the United States House of Representatives 1891–1893 James W. Gerard (1890), U.S. ambassador to Germany 1913–1917 Victor M. Allen (1892), member of the New York State Senate John F. Carew (1893), U.S. congressman from New York Harvey R. Kingsley (1893), president pro tempore of the Vermont State Senate Edward Lazansky (1895), secretary of state of New York Carl L. Alsberg (1896), 2nd commissioner of Food and Drugs, head of the Food and Drug Administration 1912–1921 Lewis Einstein (1898), U.S. ambassador to Czechoslovakia and U.S. ambassador to Costa Rica John Purroy Mitchel (1899), mayor of New York City Montgomery Schuyler Jr. (1899), U.S. minister to El Salvador and U.S. minister to Ecuador Charles H. Tuttle (1899), U.S. attorney for the Southern District of New York and 1930 Republican nominee for governor of New York Henry W. Shoemaker (1901), folklorist, historian, diplomat; U.S. ambassador to Bulgaria 1930–1933 Martin C. Ansorge (1903), U.S. congressman from New York Stanley M. Isaacs (1903), Manhattan borough president 1938–1942 Allen J. Bloomfield (1094), member of the New York State Assembly and the New York State Senate Fred Biermann (1905), U.S. congressman from Iowa John Collier (1906), U.S. commissioner of Indian Affairs Meyer Robert Guggenheim* (1907), U.S. ambassador to Portugal 1953–1954, grandson of Meyer Guggenheim Joseph C.
Calcium alginate dressings may help the production of mouse fibroblasts and in vitro, of human fibroblasts. Fibroblasts are known to be involved in the regeneration and healing of the tissues. It has been shown that calcium alginate activates human macrophages to produce TNFα (Tumor Necrosis Factor α) which is involved in the inflammatory signals and consequently wound healing process. Moreover, the clotting mechanisms during the first stage of wound healing may be improved by calcium alginate. A comparative study of hydrocolloid dressings and alginates showed that alginates gels remain on the wound for a longer period than hydrocolloids. The early use of alginates as haemostats and wound dressings and their apparent lack of toxicity are discussed.
== Career == Henriksen found work as a muralist and as a laborer on ships. For a time, he worked in Europe. Around age 30, he found theater work as a set designer, and he received his first acting role because he built the set for a production. It was around this time that he taught himself to read. For his first role, he put the entire script on tape with the help of a friend, then learned his part and all of the others. Soon afterward, he graduated from the Actors Studio and began acting in New York City. Henriksen's first film appearance was in The Outsider in 1961, as an uncredited extra. He received his first credit in his second film, 1972's It Ain't Easy. He auditioned for the role of Leon Shermer in Dog Day Afternoon (1975), but received the smaller part of an FBI agent that kills John Cazale's character. He appeared in two more films directed by Sidney Lumet: Network (1976) and Prince of the City (1981). In a 2009 interview, Henriksen called Lumet "the kind of guy that loves New York actors, because that's where he works and that's what he knows....He would give you the job that was maybe only meant for four days, and he'd give you the run of the show because he wanted to help support young actors in New York." Henriksen had supporting roles in a variety of films, including the science-fiction film Close Encounters of the Third Kind (1977) and the horror film Damien - Omen II (1978). He also had co-starring roles in the low-budget horror film Mansion of the Doomed (1976) and the Italian-produced science fiction film The Visitor (1979).
== Etymology == The earliest known record of the name Belize appears in the journal of the Dominican priest Fray José Delgado, dating to 1677. Delgado recorded the names of three major rivers that he crossed while travelling north along the Caribbean coast: Rio Soyte (Sittee River), Rio Kibum Sibun River, and Rio Balis (Belize River). The waterways' names were provided to Delgado by his translator. It has been proposed that Delgado's "Balis" was actually the Mayan word belix (or beliz), meaning "muddy water", although no such Mayan word actually exists. More recently, it has been proposed that the name comes from the Mayan phrase bel Itza ("the way to Itza"). In the 1820s, the legend grew up that the toponym Belize derived from the Spanish pronunciation of the name of a Scottish buccaneer, Peter Wallace, said to have established a settlement at the mouth of the Belize River in 1638. There is no proof that buccaneers settled in this area and there is no evidence of the very existence of Wallace. Writers and historians have suggested several other possible etymologies, including postulated French and African origins.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.